Review





Similar Products

nucleospin mirna plasma kit  (MACHEREY NAGEL)
96
MACHEREY NAGEL nucleospin mirna plasma kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Nucleospin Mirna Plasma Kit, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/NucleoSpin+miRNA%2C+Mini+kit+for+miRNA+and+RNA+purification/pmc13237519-162-10-14
Average 96 stars, based on 1 article reviews
nucleospin mirna plasma kit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
nucleospin mirna kit  (MACHEREY NAGEL)
96
MACHEREY NAGEL nucleospin mirna kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Nucleospin Mirna Kit, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/NucleoSpin+miRNA%2C+Mini+kit+for+miRNA+and+RNA+purification/pm42143393-70-13-16
Average 96 stars, based on 1 article reviews
nucleospin mirna kit - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
allprep dna rna micro kit  (Qiagen)
98
Qiagen allprep dna rna micro kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Allprep Dna Rna Micro Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/AllPrep+DNA%2FRNA+Micro+Kit/bio_rxiv__64898__2026__05__09__724006-263-17-21
Average 98 stars, based on 1 article reviews
allprep dna rna micro kit - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
allprep dna rna kit  (Qiagen)
99
Qiagen allprep dna rna kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Allprep Dna Rna Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/AllPrep+DNA%2FRNA%2FmiRNA+Universal+Kit/pmc13161541-236-10-13
Average 99 stars, based on 1 article reviews
allprep dna rna kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
micro rna purification kit  (Qiagen)
99
Qiagen micro rna purification kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Micro Rna Purification Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/miRNeasy+Micro+Kit/us12624086-435-10-17
Average 99 stars, based on 1 article reviews
micro rna purification kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
allprep dna rna mirna universal kit  (Qiagen)
99
Qiagen allprep dna rna mirna universal kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Allprep Dna Rna Mirna Universal Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/AllPrep+DNA%2FRNA%2FmiRNA+Universal+Kit/bio_rxiv__64898__2026__05__05__723050-85-7-11
Average 99 stars, based on 1 article reviews
allprep dna rna mirna universal kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
allprep dna rna mirna kit  (Qiagen)
99
Qiagen allprep dna rna mirna kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Allprep Dna Rna Mirna Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/AllPrep+DNA%2FRNA%2FmiRNA+Universal+Kit/med_rxiv__64898__2026__05__05__26351600-142-13-16
Average 99 stars, based on 1 article reviews
allprep dna rna mirna kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
allprep dna rna mirna extraction kit  (Qiagen)
99
Qiagen allprep dna rna mirna extraction kit
Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma <t>miRNA</t> levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.
Allprep Dna Rna Mirna Extraction Kit, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rna+for+mirna/AllPrep+DNA%2FRNA%2FmiRNA+Universal+Kit/pmc13159456-93-12-16
Average 99 stars, based on 1 article reviews
allprep dna rna mirna extraction kit - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma miRNA levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.

Journal: Oncology Letters

Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

doi: 10.3892/ol.2026.15669

Figure Lengend Snippet: Identification of circulating OAA1-captured miRNAs associated with lung cancer and resistance to nivolumab. (A) Lectin histochemistry using OAA1 on surgically resected lung cancer tissues (×200 magnification). The left panel shows OAA1 lectin staining in normal lung tissue, whereas the right panel shows OAA1 lectin staining in lung cancer tissue. (B) In the discovery phase, plasma samples from two patients with NSCLC with PD were collected before and after nivolumab treatment. After plasma purification using an OAA1 column, microarray analysis was performed to identify candidate miRNAs (miR-320a, miR-320b, and miR-3613-5p) associated with nivolumab resistance. In the validation phase, plasma samples from 48 patients with NSCLC (before nivolumab treatment) were analyzed with and without OAA1 column purification. The levels of the identified miRNAs were quantified using TaqMan qPCR, and statistical analyses were conducted to evaluate their predictive and prognostic values as biomarkers for nivolumab resistance. (C) Microarray analysis of OAA1-captured plasma miRNAs in patients with PD after nivolumab treatment reveals several upregulated candidate miRNAs, including miR-320a, miR-320b, and miR-3613-5p. (D) Relative levels of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with NSCLC (n=48) and healthy controls (n=11) with and without OAA1 enrichment. Plasma miRNA levels were quantified by reverse transcription-qPCR. Relative miRNA levels were normalized to miR-16-5p and calculated using the 2 −ΔΔCq method, with the mean level of healthy volunteers serving as the calibrator. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miRNA/miR, microRNA; NSCLC, non-small cell lung cancer; OAA1, Oscillatoria agardhii agglutinin 1; PD, progressive disease; qPCR, quantitative polymerase chain reaction.

Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

Techniques: Staining, Clinical Proteomics, Purification, Microarray, Biomarker Discovery, Reverse Transcription, MANN-WHITNEY, Real-time Polymerase Chain Reaction

Differential expression of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with non-small cell lung cancer with PR or SD + PD. (A) Relative levels of miR-320a, miR-320b, and miR-3613-5p without OAA1 enrichment. (B) With OAA1 column enrichment. Plasma miRNA levels were quantified by reverse transcription-quantitative polymerase chain reaction and are shown as relative abundance using the 2 −ΔCq method normalized to miR-16-5p. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; SD, stable disease; PD, progressive disease; PR, partial response.

Journal: Oncology Letters

Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

doi: 10.3892/ol.2026.15669

Figure Lengend Snippet: Differential expression of miR-320a, miR-320b, and miR-3613-5p in pre-treatment plasma from patients with non-small cell lung cancer with PR or SD + PD. (A) Relative levels of miR-320a, miR-320b, and miR-3613-5p without OAA1 enrichment. (B) With OAA1 column enrichment. Plasma miRNA levels were quantified by reverse transcription-quantitative polymerase chain reaction and are shown as relative abundance using the 2 −ΔCq method normalized to miR-16-5p. Statistical significance was determined using the Mann-Whitney U test. Data are presented as median with 95% confidence intervals. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; SD, stable disease; PD, progressive disease; PR, partial response.

Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

Techniques: Quantitative Proteomics, Clinical Proteomics, Reverse Transcription, Real-time Polymerase Chain Reaction, MANN-WHITNEY

ROC curve analysis of miRNAs for predicting non-response to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer treated with nivolumab. (A) ROC curves for circulating miR-320a, miR-320b, and miR-3613-5p without OAA1 column enrichment. (B) With OAA1 enrichment. AUC, area under the curve; CI, confidence interval; miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; ROC, receiver operating characteristic.

Journal: Oncology Letters

Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

doi: 10.3892/ol.2026.15669

Figure Lengend Snippet: ROC curve analysis of miRNAs for predicting non-response to immune checkpoint inhibitor therapy in patients with non-small cell lung cancer treated with nivolumab. (A) ROC curves for circulating miR-320a, miR-320b, and miR-3613-5p without OAA1 column enrichment. (B) With OAA1 enrichment. AUC, area under the curve; CI, confidence interval; miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; ROC, receiver operating characteristic.

Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

Techniques:

Kaplan-Meier analysis for OS based on pre-treatment plasma levels of miR-320a, miR-320b, and miR-3613-5p in patients with non-small cell lung cancer treated with nivolumab (n=48). (A) Kaplan-Meier curves comparing the OS between the high- and low-expression groups for each miRNA without OAA1 column enrichment. (B) Kaplan-Meier curves for the same miRNAs with the OAA1 enrichment. The number of patients in each group is indicated in the legends. Cutoff values for high/low expression were determined using receiver operating characteristic analysis. P-values are shown; *P<0.05. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; OS, overall survival.

Journal: Oncology Letters

Article Title: Lectin-captured plasma microRNAs predict response and survival in patients with non-small cell lung cancer treated with nivolumab

doi: 10.3892/ol.2026.15669

Figure Lengend Snippet: Kaplan-Meier analysis for OS based on pre-treatment plasma levels of miR-320a, miR-320b, and miR-3613-5p in patients with non-small cell lung cancer treated with nivolumab (n=48). (A) Kaplan-Meier curves comparing the OS between the high- and low-expression groups for each miRNA without OAA1 column enrichment. (B) Kaplan-Meier curves for the same miRNAs with the OAA1 enrichment. The number of patients in each group is indicated in the legends. Cutoff values for high/low expression were determined using receiver operating characteristic analysis. P-values are shown; *P<0.05. miR, microRNA; OAA1, Oscillatoria agardhii agglutinin 1; OS, overall survival.

Article Snippet: After thorough vortex mixing, the miRNA was purified using the NucleoSpin miRNA Plasma kit (Macherey-Nagel, Germany) with DNA digestion treatment, according to the manufacturer's protocol.

Techniques: Clinical Proteomics, Expressing